A Phase 2 Prospective, Randomized, Double-Arm, Deferred Treatment, Open Label, Repeat Dose, Safety and Efficacy Sudy of Autologous Neo-Kidney Augment (NKA) in Subjects With Type 2 Diabetes and Chronic Kidney Disease

Trial Profile

A Phase 2 Prospective, Randomized, Double-Arm, Deferred Treatment, Open Label, Repeat Dose, Safety and Efficacy Sudy of Autologous Neo-Kidney Augment (NKA) in Subjects With Type 2 Diabetes and Chronic Kidney Disease

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs Autologous cultured kidney tissue cells (Primary)
  • Indications Renal failure
  • Focus Therapeutic Use
  • Sponsors RegenMedTX
  • Most Recent Events

    • 10 Jan 2017 Status changed from not yet recruiting to recruiting.
    • 21 Jul 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top